X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) has received an average rating of “Buy” from the seven research firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $20.00.
A number of analysts have recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of X4 Pharmaceuticals in a report on Monday, June 14th. Zacks Investment Research upgraded shares of X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, August 7th. Finally, Roth Capital restated a “buy” rating and issued a $27.00 price target (up from $23.00) on shares of X4 Pharmaceuticals in a report on Friday, June 11th.
NASDAQ XFOR traded up $0.27 during trading on Friday, reaching $5.54. 379,665 shares of the company’s stock traded hands, compared to its average volume of 149,341. The company has a debt-to-equity ratio of 0.38, a current ratio of 7.73 and a quick ratio of 7.73. The firm has a market cap of $137.68 million, a price-to-earnings ratio of -1.45 and a beta of 0.54. The company’s 50 day simple moving average is $5.35 and its two-hundred day simple moving average is $7.24. X4 Pharmaceuticals has a 12-month low of $4.25 and a 12-month high of $10.70.
In other X4 Pharmaceuticals news, General Counsel Derek M. Meisner sold 8,332 shares of X4 Pharmaceuticals stock in a transaction that occurred on Tuesday, August 17th. The shares were sold at an average price of $5.10, for a total transaction of $42,493.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Paula Ragan sold 13,448 shares of X4 Pharmaceuticals stock in a transaction that occurred on Tuesday, August 17th. The shares were sold at an average price of $5.10, for a total transaction of $68,584.80. The disclosure for this sale can be found here. Insiders sold a total of 48,701 shares of company stock valued at $261,587 over the last quarter. 4.90% of the stock is owned by company insiders.
Large investors have recently bought and sold shares of the company. BNP Paribas Arbitrage SA increased its holdings in shares of X4 Pharmaceuticals by 80.8% during the 1st quarter. BNP Paribas Arbitrage SA now owns 5,609 shares of the company’s stock valued at $48,000 after purchasing an additional 2,507 shares in the last quarter. LMR Partners LLP purchased a new position in shares of X4 Pharmaceuticals during the 2nd quarter valued at approximately $66,000. Morgan Stanley increased its holdings in shares of X4 Pharmaceuticals by 227.8% during the 2nd quarter. Morgan Stanley now owns 10,242 shares of the company’s stock valued at $67,000 after purchasing an additional 7,118 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new position in shares of X4 Pharmaceuticals during the 1st quarter valued at approximately $91,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of X4 Pharmaceuticals during the 2nd quarter valued at approximately $85,000. 66.75% of the stock is owned by hedge funds and other institutional investors.
X4 Pharmaceuticals Company Profile
X4 Pharmaceuticals, Inc operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003.
Featured Story: How to start trading in the forex market?
Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.